Brickell Biotech, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics primarily for dermatologic, autoimmune, inflammatory, and other serious conditions. Its core products include sofpironium bromide, a late-stage topical treatment for primary axillary hyperhidrosis, and a pipeline of novel drug candidates targeting autoimmune and inflammatory diseases, such as BBI-02, a first-in-class oral DYRK1A inhibitor, and BBI-10, a preclinical STING inhibitor. The company also develops next-generation kinase inhibitors for autoimmune and neuroinflammatory conditions. Brickell engages in global development and commercialization efforts, with strategic partnerships, notably with Kaken Pharmaceutical for the commercial launch of sofpironium bromide in Japan and collaborations with Voronoi Inc. for the DYRK1A inhibitor platform. Recently, Brickell Biotech has undergone significant advancements including the acquisition of exclusive global rights to a portfolio of STING inhibitors from Carna Biosciences in early 2022, expanding its presence in immunology and inflammation. It also entered into an exclusive agreement with Voronoi Inc. for the DYRK1A inhibitor platform, with plans to advance BBI-02 into Phase 1 clinical trials. In 2022, Brickell rebranded as Fresh Tracks Therapeutics to emphasize its commitment to innovative therapies beyond dermatology, reflecting a strategic shift towards treating autoimmune and inflammatory diseases. The company raised $6.6 million in early 2023 through an at-the-market program to enhance liquidity and support ongoing clinical development efforts. Founded in 2011 and headquartered in Boulder, Colorado, Brickell operates within the pharmaceutical and biotechnology industries, targeting patients with unmet medical needs in dermatology, autoimmune, and inflammatory disorders. The company’s management team brings extensive experience from global pharmaceutical firms, focusing on advancing promising clinical-stage assets through development and commercialization in the U.S., Japan, and other international markets. Brickell’s robust pipeline and recent strategic alliances position it for growth in specialized therapeutic markets with a focus on innovative drug platforms addressing chronic and debilitating diseases.
Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
Boundless Bio: An Underestimated Biotech With A First-In-Class EcDNA Targeted Kinesin Degrader
PRESS RELEASE: NACON announces the temporary suspension of trading in its shares on Euronext Paris
Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway
Boundless Bio Announces Portfolio Prioritization and Runway Extension
Boundless Bio Announces Pipeline and Leadership Updates
Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights
Fresh Tracks Therapeutics Announces Second Adjournment of Special Meeting of Stockholders
Fresh Tracks Therapeutics Announces Adjournment of Special Meeting of Stockholders
Fresh Tracks Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Fresh Tracks Therapeutics Announces Board Approval of Plan of Liquidation and Dissolution
Fresh Tracks Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Fresh Tracks Announces $8.25 Million Buyout of Its Right to Receive Future Sofpironium Bromide Payments from Botanix
Fresh Tracks Therapeutics to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 10, 2022
Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q2 2022 Results - Earnings Call Transcript
Brickell Biotech (BBI) Stock: 1-For-45 Reverse Split Announced
Brickell Biotech (BBI) Stock Gains 50% Ahead of Meeting to Prevent Delisting
3 Penny Stocks To Watch After GDP Report
Top Penny Stocks To Buy? 4 Biotech Stocks To Watch Now
Brickell (BBI) Reports Q1 Loss, Lags Revenue Estimates